Hypoparathyroidism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Hypoparathyroidism Market Outlook

Thelansis’s “Hypoparathyroidism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypoparathyroidism   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypoparathyroidism Overview

Hypoparathyroidism manifests as a condition typified by decreased serum calcium levels and elevated serum phosphorus levels attributable to deficient secretion or activity of parathyroid hormone (PTH). Etiologically, hypoparathyroidism can arise as a component of either pluriglandular autoimmune disorders or complex congenital anomalies, exemplified by autosomal dominant DiGeorge syndrome or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes. Moreover, isolated or idiopathic hypoparathyroidism denotes cases devoid of accompanying systemic abnormalities. The etiology of hypoparathyroidism is multifactorial and encompasses:

1. Developmental anomalies of the parathyroid glands
2. Iatrogenic injuries to the parathyroid glands
3. Diminished parathyroid gland function due to dysregulated regulatory mechanisms
4. Impaired responsiveness to PTH

Manifestations of hypoparathyroidism arise from the consequences of reduced serum calcium levels on various organ systems, and their severity correlates with the extent and rapidity of hypocalcemia. Persistent hypoparathyroidism poses a significant risk following central neck surgeries, particularly bilateral procedures or simultaneous thyroidectomy and parathyroidectomy, as well as in cases of autoimmune thyroid disorders, central neck dissections, substernal goiters, procedures performed by low-volume surgeons, and prior gastric bypass surgeries. The FDA has sanctioned Natpara (rhPTH(1-84)) for managing hypoparathyroidism in adults. Natpara represents a novel once-daily subcutaneously injectable recombinant PTH formulation, the sole prescription medication approved by the FDA for controlling hypocalcemia when co-administered with calcium and vitamin D in adult hypoparathyroidism patients.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hypoparathyroidism  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034